Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: A short term pilot study

Cytokine

Volumn 27, Issue 6, 2004, Pages 159-165

  George, Magdalene M ^a   Li, S David ^a   Mindikoglu, Ayse L ^a   Baluch, Mehdi H ^a   Dhillon, Sonu ^a   Farr, Deborah ^a   Van Thiel, David H ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b St Luke's Medical Center   (United States)

Author keywords

alanine aminotransferase; ALT; aspartate aminotransferase; AST; blood urea nitrogen; BUN; COX; COX II; cyclooxygenase; EIA; enzyme immunoassay; G CSF; granulocyte colony stimulating factor; HCV; Hepatitis C; hepatitis C virus; IL 8; Interferon; interleukin 8; Platelets

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 18; PADGEM PROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; ROFECOXIB; THROMBOPOIETIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FIBROSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER EXAMINATION; MALE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERLEUKIN-13; INTERLEUKIN-8; MEMBRANE PROTEINS; MIDDLE AGED; P-SELECTIN; POLYETHYLENE GLYCOLS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RIBAVIRIN; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 4043071273     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.05.005     Document Type: Article

References (23)

1. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic hepatitis. N Engl J Med. 332:1995;1457-1462
2. Tacke F., Trautwein C., Zhao S., Andreef M., Manns M.P., Ganser A., et al. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver disease shows maintained gene expression in different etiologies of liver disease. Liver. 22:2002;205-212
3. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest. 45:1966;645-657
4. Hoofnagle J.H. Thrombocytopenia during interferon alfa therapy. J Am Med Assoc. 266:1991;849-850
5. Ernstoff M.S., Kirkwood J.M. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha 2. Am J Med. 76:1984;593-596
6. Epstein R.J. Eicosanoid biosynthesis is a key therapeutic drug target. Human molecular biology. 2003;295-297 Cambridge University Press
7. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:1998;97-120
8. Cheng Y., Austin S.C., Rocca B., Koller B.H., Coffman T.M., Grosser T., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 296:2002;539-541
9. Epstein R.J. Bioactive lipids and inflammatory cytokines. Human molecular biology. 2003;293-294 Cambridge University Press
10. De Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haemotologica. 86:2001;349-356
11. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 86:2001;746-756
12. Cerletti C. Platelet-leukocyte interactions relevant to vascular damage and thrombosis. Gresele P., Page C.P., Fuster V., Vermylen J. Platelets in thrombotic and non thrombotic disorders. 2002;412-431 Cambridge University Press
13. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 99:2002;7634-7639
14. Chenevard R., Hurlimann D., Bechir M., Enseleit F., Spieker L., Hermann M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 107:2003;405-409
15. Sala A., Folco C. Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation? Biochem Biophys Res Commun. 283:2001;1003-1006
16. Shebuski R.J., Kilgore K.S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 300:2002;729-735
17. Furie B., Furie B.C., Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signaling and cell adhesion. Thromb Haemost. 86:2001;214-221
18. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 104:2001;1533-1537
19. Weyrich A.S., Elstad M.R., McEver R.P., McIntyre T.M., Moore K.L., Morrissey J.H., et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 97:1996;1525-1534
20. Ignarro L.J., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res. 90:2002;21-28
21. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1 beta synthesis. J Cell Biol. 154:2001;485-490
22. Evangelista V., Manarini S., Coller B.S., Smyth S.S. Role of P-selectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion. J Thromb Haemost. 1:2003;1048-1054
23. Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 136:2002;161-172